Blood:树突细胞的IL-6失调通过经典信号传导引发移植物抗宿主病

2019-10-04 MedSci MedSci原创

同种异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素6 (IL-6)调节异常。IL-6可通过多种途径介导其作用,包括经典、反式和群集信号。鉴于近年来有多种药物可以抑制这些离散信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至关重要。Wilkinson等人发现受体树突细胞(DC)分泌的IL-6启动了这种细胞因子的系统失调。靶向敲除T细胞中的IL-6受体(IL

同种异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素6 (IL-6)调节异常。IL-6可通过多种途径介导其作用,包括经典、反式和群集信号。鉴于近年来有多种药物可以抑制这些离散信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至关重要。

Wilkinson等人发现受体树突细胞(DC)分泌的IL-6启动了这种细胞因子的系统失调。靶向敲除T细胞中的IL-6受体(IL-6R)后,抑制DC驱动的经典信号可消除致病性供体Th17/Th22细胞的分化,患者从而获得长期存活。

移植后,供体DC承担同样的角色,维持经典的IL-6信号依赖性的GVHD反应。此外,移植后的群集信号通路并不活跃,但用sgp130Fc抑制反式信号通路可促进发生严重的慢性皮肤GVHD。后者是多功能性Th22细胞扩增过度的结果,耗竭IL-22或抑制IL-6R可逆转这一结果。重要的是,抑制IL-6经典信号并不影响移植物抗白血病的作用。

总之,本研究数据强调了IL-6经典信号及其下游Th17/Th22分化是alloSCT后的关键治疗靶点。

原始出处:

Andrew N. Wilkinson, et al.IL-6 dysregulation originates in dendritic cells and initiates graft-versus-host disease via classical signaling.Blood 2019 :blood.2019000396; doi: https://doi.org/10.1182/blood.2019000396

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-05-12 xuyong535
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-10-06 kzlchina
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-10-06 wincls
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1693294, encodeId=a30e16932940a, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Fri Jun 12 05:34:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745330, encodeId=22401e45330ec, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue May 12 23:34:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273784, encodeId=a31612e3784e8, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404728, encodeId=ae3b1404e28e5, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419727, encodeId=daa61419e272d, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620741, encodeId=dac81620e41e7, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Oct 06 13:34:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]

相关资讯

Blood:树突细胞不能正常激活CD4 T细胞时可导致骨髓增生

中心点:骨髓增生可能是DC-CD4 T细胞相互作用缺陷以及DCs数目缺陷的结果。摘要:树突细胞(DCs)是适应性免疫应答起始的关键细胞。近期,有研究提示DCs具有抑制骨髓增殖的作用。在构成性敲除DCs的小鼠研究和由GATA2或IRF8突变引起DCs先天性缺陷的患者中均可观察到骨髓增生性疾病(MPD)。DC缺陷和MPD之间的机制关联尚不明确。目前流行的模型表明数目性树突细胞缺陷通过代偿性髓系分化导致

Mol Med Rep:树突细胞中CD86的沉默能够调控过敏性鼻炎患者T细胞中细胞因子的产生

最近,有研究人员在来源于过敏性鼻炎(AR)患者的外周血样中调查了共刺激分子T淋巴细胞活化抗原CD86在树突细胞(DCs)中的表达和作用,并与那些来源于健康个体的样本进行了比较。研究发现,与对照组相比,来源于AR患者外周血样本的成熟DCs细胞表达更高水平的共刺激分子CD86,而不是CD80。CD86在DCs中的表达水平在转染了慢病毒载体siRNA后显著减少。更多的是,与DCs细胞共培养的T细胞产生的

Int Arch Allergy Immunol:Zeste同源体2增强子的表观修饰能够调节树突细胞的激活

过敏原免疫疗法(AIT)是目前过敏性鼻炎(AR)唯一的病因学和可能的治愈疗法。最近,有研究人员探索调查了AIT中,表观调节因子zeste同源体2增强子(EZH2)在树突细胞(DCs)激活中的作用。研究包括了56名AR患者的临床信息,他们均接受了AIT治疗。其中,30名受试者进行的是皮下免疫治疗(SCTI),26名受试者进行的是舌下免疫治疗(SLIT)。研究发现,EZH2的表达在循环mDCs和pDC

Blood:体外激活和依鲁替尼治疗可恢复CLL Vγ9Vδ2-T细胞的抗CLL细胞的细胞毒性作用

中心点:健康的Vγ9Vδ2-T细胞可识别裂解CLL细胞,但CLL患者来源的Vγ9Vδ2-T细胞的细胞毒性和细胞因子合成受损。用自体moDCs在体外激活Vγ9Vδ2-T细胞可逆转其功能障碍,依鲁替尼可促进产生抗肿瘤的TH1表型。摘要:自体(αβ)T细胞为基础的治疗策略用于慢性淋巴细胞白血病(CLL)的疗效一直较为温和。具有强力的抗淋巴瘤活性的细胞毒性T淋巴细胞通过主要组织相容性复合物(MHC)非依赖

Immunity:树突细胞指导T细胞发挥作用的新型分子机制

图片摘自:imgarcade.com日前,刊登在国际杂志Immunity上的一项研究报告中,来自圣路易斯大学(Saint Louis University)的研究人员通过研究揭示了机体免疫系统中的树突细胞如何指挥T淋巴细胞学习对机体自身细胞的耐受性。机体免疫系统往往会通过避免过度反应或反应不足所带来的危险来维持机体健康,而机体免疫功能不全的个体往往非常容易患病,从另一方面来讲,机体免疫系统如果过于

PNAS:树突细胞参与调节过敏反应

深入认识感染可能有助于科学家们理解过敏症和开发新的治疗方法。在一项新研究中,英国爱丁堡大学研究人员对免疫系统的研究揭示出一种参与身体对诸如花粉或宠物毛发之类的过敏原产生的免疫反应的细胞所发挥的作用。这种细胞被称作树突细胞,已知它起着协调身体对感染产生免疫反应的作用。它是通过让免疫系统激活抵抗感染的白细胞来发挥功能的。 研究人员证实当身体免疫反应过于活跃且可能造成伤害时,树突细胞也能够在抑制这种免